Tag Archives: BioMarketing Insight

Gilead makes breakout M&A move; buys CAR-T wunderkind Kite Pharma for $12 billion.

The News: Gilead Sciences Inc. (Foster City CA) announced it would buy cancer-immune therapy company Kite Pharma Inc. (Santa Monica CA) for about $11.9 billion to bolster its hugely successful but… Read more »

Novartis gets FDA nod for breakthrough leukemia treatment Kymriah; with a cost of $450,000, who’s going to get it?

The News: Novartis AG (Basel CHE) has obtained approval from the US Food and Drug Administration (FDA) for its Kymriah (tisagenlecleucel or CTL019) to treat children and young adults with… Read more »

CAR-T Therapy: Personalized medicine with the promise of a cure; payers will decide who gets it

The News: Swiss drug giant Novartis AG has drawn widespread praise and a rising dose of controversy pertaining to its breakthrough CAR-T therapy CTL019. The medicine is under review to… Read more »